Atossa Therapeutics, Inc.
ATOS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | -0.85 | 0.37 | -0.34 |
| FCF Yield | -6.77% | -6.87% | -5.90% | -2.49% |
| EV / EBITDA | -5.86 | -3.25 | -6.78 | -18.24 |
| Quality | ||||
| ROIC | -15.67% | -11.35% | -10.00% | -8.67% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.86 | 0.89 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -21.63% | 15.36% | -48.13% | -4.98% |
| Safety | ||||
| Net Debt / EBITDA | 6.87 | 9.70 | 9.95 | 11.72 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -45,225.00 | -26,212.50 | -15,277.50 | -35,122.50 |